Sector News

Ranbaxy India head Rajeev Sibal latest to quit

July 8, 2015
Life sciences
In a continuing spate of high-level executive exits, Rajeev Sibal, head of India operations at Ranbaxy, has put in his papers. Sibal — a pharma industry veteran — is expected to join drug company Lupin later this month, where he will be responsible for India and other emerging markets, sources told TOI. 
 
With Sibal’s exit, the only other senior executive left behind from erstwhile Ranbaxy — which was acquired by Sun Pharma — is Subodh Marwaha, head consumer (OTC), besides the MD, Arun Sawhney. Sun Pharma, run by billionaire businessman Dilip Shanghvi, is executing a massive manpower restructuring in the company he acquired recently. The rejig is expected to involve 150-odd senior executives and flatten roles in even R&D and certain manufacturing facilities. 
 
Sibal, who is an old Ranbaxy hand having headed several key departments in the company earlier, was brought back from Glenmark Pharma to head the India operations in 2013. When contacted, he declined comment, while a Sun Pharma spokesperson said that the company does not comment on people movements. 
 
Sun Pharma has executed three rounds of manpower rationalisation over the past few months, starting from the top-most level of president, percolating to vice-presidents and directors in the latest round. In the latest round, over a dozen top executives have been asked to leave the company, making it one of the biggest manpower rejigs in recent times. 
 
“The massive manpower restructuring was done only after April, when all the regulatory clearances had come for Sun Pharma-Ranbaxy merger”, an industry expert said. 
 
Sun Pharma completed the $4-billion acquisition of Ranbaxy in March, after the deal was announced in April last year. After taking charge, Sun Pharma made it a six-day week in Ranbaxy from a five-day one, and introduced frugal policies for domestic and international travel, the source added. 
 
By Rupali Mukherjee
 

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach